Skeletal metastases

Decreasing tumor burden by targeting the bone microenvironment

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurahle and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-β. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.

Original languageEnglish (US)
Pages (from-to)1333-1342
Number of pages10
JournalJournal of Cellular Biochemistry
Volume102
Issue number6
DOIs
StatePublished - Dec 15 2007
Externally publishedYes

Fingerprint

Tumor Burden
Tumors
Bone
Neoplasm Metastasis
Bone and Bones
Neoplasms
Cells
Tumor Microenvironment
Osteoblasts
Transforming Growth Factors
Osteoclasts
Growth
Skeleton
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins
Animals
Animal Models
Cytokines

Keywords

  • Bisphosphonates
  • Bone metastases
  • Endothelin-1
  • Hypoxia
  • Osteoblastic metastases
  • Osteolytic metastases
  • Transforming growth factor beta
  • Wnt signaling

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Skeletal metastases : Decreasing tumor burden by targeting the bone microenvironment. / Chirgwin, John; Guise, Theresa.

In: Journal of Cellular Biochemistry, Vol. 102, No. 6, 15.12.2007, p. 1333-1342.

Research output: Contribution to journalArticle

@article{1b2e99046d124d509d3eae5d9135cfc1,
title = "Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment",
abstract = "Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurahle and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-β. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.",
keywords = "Bisphosphonates, Bone metastases, Endothelin-1, Hypoxia, Osteoblastic metastases, Osteolytic metastases, Transforming growth factor beta, Wnt signaling",
author = "John Chirgwin and Theresa Guise",
year = "2007",
month = "12",
day = "15",
doi = "10.1002/jcb.21556",
language = "English (US)",
volume = "102",
pages = "1333--1342",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Skeletal metastases

T2 - Decreasing tumor burden by targeting the bone microenvironment

AU - Chirgwin, John

AU - Guise, Theresa

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurahle and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-β. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.

AB - Several common cancers often metastasize to the skeleton in advanced disease. Bone metastases are incurahle and cause protracted, severe symptoms. Growth of tumor in bone is driven by a vicious cycle: tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines. The bone-derived factors fuel the vicious cycle by acting back on the tumor cells. The vicious cycle offers novel targets for the treatment of advanced cancers. Treatments can inhibit bone cells (osteoclasts and osteoblasts) that are stimulated by tumor-secreted factors. Drugs can also inhibit tumor responses to factors enriched in the bone microenvironment, such as transforming growth factor-β. Animal models show that these approaches, especially combination treatments, can reduce tumor burden. The results suggest a novel paradigm in which tumor growth can be effectively inhibited by drugs that target cells in the bone microenvironment and not the tumor cells themselves.

KW - Bisphosphonates

KW - Bone metastases

KW - Endothelin-1

KW - Hypoxia

KW - Osteoblastic metastases

KW - Osteolytic metastases

KW - Transforming growth factor beta

KW - Wnt signaling

UR - http://www.scopus.com/inward/record.url?scp=36849060195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849060195&partnerID=8YFLogxK

U2 - 10.1002/jcb.21556

DO - 10.1002/jcb.21556

M3 - Article

VL - 102

SP - 1333

EP - 1342

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 6

ER -